PTX3 and obesity due to melanocortin 4 receptor deficiency: The current findings however indicate a novel link between obesity and plasma PTX3 in ACS, and understanding the underlying mechanisms will likely lead to novel potential prevention and treatment strategies to improve ACS prognosis in both obese and non-obese patients.